Meredith Hay, Ph.D.

President & Chief Science Officer

Dr. Hay is the visionary and one of the inventors of the founding technology. She has over 25 years of experience in neuroscience and cardiovascular neurophysiology.  She is the former Executive Vice President and Chief Operating Officer for the University of Arizona for former Vice President for Research, University of Iowa.  She currently is a tenured professor at the University of Arizona College of Medicine. Dr. Hay has generated over $10 M in external R&D funding and nearly 20 NIH and related grants.


Bruce Coull, M.D.

Chief Medical Officer

Dr. Coull is internationally known for his expertise in stroke, vascular neurology and brain inflammation and has over 35 years of experience in neurology and clinical trial management. He is a professor of Neurology and Medicine, Vice dean for clinical affairs at the University of Arizona College of Medicine – Tucson and served as Chief Medical Officer for The University of Arizona Physicians. Dr. Coull is author and co-author of over 130 peer-reviewed journals, book chapters and other publications. He is an expert in human vascular neurology and has been voted one of the "Best Doctors in America" 2008, 2009, 2010, 2011, 2013, 2014.


Rodney Lax, Ph.D.

Peptide Chemistry Development

Has over 35 years of experience in peptide chemistry, manufacturing and therapeutic development. In 1997, he joined WHERL GmbH (which in 1998 became PolyPeptide Laboratories GmbH) as Director of Sales & Marketing. In February 2003 he moved to the PolyPeptide Laboratories, Inc. in California as Senior Director of Business Development. He received his lectureship (Habilitation) in Physiological Chemistry in 1978 and became an Associate Professor at the University of Essen in 1985. After leaving academia in 1986, he then worked for a number of small biotech companies involved in peptide-based pharmaceuticals in Northern Germany, including Bissendorf Peptides GmbH, Pharma Biotechnology Hannover GmbH and Saxon Biochemicals.


Chistopher Holmes, Ph.D.

Director of CMC and Regulatory Compliance 

Has over 25 years experience in biochemistry and peptide therapeutic development. From 1995-2001, Dr. Holmes served as Director of Chemistry for Glaxo-Wellcome/Affiymax and led the small molecule library group within Affymax.   In 2001, he spent the next 10 years as Executive Director at Affymax and was responsible forall Chemistry, Manufacturing and Controls (CMC) for the development of Omontys becoming the first PEGylated synthetic peptide approved by the FDA.  Chris received in PhD in organic chemistry in 1986 from UC-Berkeley and postdoctoral training at Stanford University.